Patents Assigned to Cetus Corporation
-
Patent number: 4800159Abstract: The present invention is directed to a process for amplifying and detecting any target nucleic acid sequence contained in a nucleic acid or mixture thereof. The process comprises treating separate complementary strands of the nucleic acid with a molar excess of two oligonucleotide primers, extending the primers to form complementary primer extension products which act as templates for synthesizing the desired nucleic acid sequence, and detecting the sequence so amplified. The steps of the reaction may be carried out stepwise or simultaneously and can be repeated as often as desired.In addition, a specific nucleic acid sequence may be cloned into a vector by using primers to amplify the sequence, which contain restriction sites on their non-complementary ends, and a nucleic acid fragment may be prepared from an existing shorter fragment using the amplification process.Type: GrantFiled: December 17, 1986Date of Patent: January 24, 1989Assignee: Cetus CorporationInventors: Kary B. Mullis, Henry A. Erlich, Norman Arnheim, Glenn T. Horn, Randall K. Saiki, Stephen J. Scharf
-
Patent number: 4798787Abstract: Antibodies exhibit specificity toward single amino acid differences between proteins. These antibodies may be produced by synthesizing a peptide of the appropriate amino acid sequence contained in the protein, immunizing a host with the peptide, and extracting sera from the host to obtain the antibodies. The antibodies and the desired protein are then immunoprecipitated under conditions of partial denaturation to expose the epitope of the protein. The antibodies may be used for diagnostic or therapeutic purposes.Type: GrantFiled: October 17, 1984Date of Patent: January 17, 1989Assignee: Cetus CorporationInventors: Francis P. McCormick, Gail L. Wong, Robin Clark, Norman Arnheim, Danute E. Nitecki
-
Patent number: 4797491Abstract: Bifunctional chemicals useful for linking aldehyde containing moieties to moieties containing functionalities which are or can be reactive with sulfhydryl are claimed and have the formula:L--S--(CH.sub.2).sub.n1 --CONH--SPACER--NH--Xwherein L is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl;n.sub.1 =2-4;X is selected from:--CO--Y--CONHNH.sub.2, a hydrazide; ##STR1## a hydrazine; ##STR2## a hydrazine; --CO--Y--NH--CONHNH.sub.2, a semicarbazide; and--CO--Z--NH--CSNHNH.sub.2, a thiosemicarbazide;wherein Y is alkylene or oxaalkylene and Z is alkylene or a polypeptide residue bridging the N-terminal amino group and C-terminal carboxy group thereof;the SPACER is oxaalkylene or oxaalkylene substituted with hydroxyl and specifically includes residues having formulas selected from--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --(a)wherein each n2 is independently 2-4 and ##STR3## wherein n3 is 2-6.Type: GrantFiled: March 17, 1986Date of Patent: January 10, 1989Assignee: Cetus CorporationInventors: Danute E. Nitecki, Margaret Moreland
-
Patent number: 4797388Abstract: An improved pharmaceutical composition contains galactitol as carrier for the therapeutic agent. One example is a lyophilized composition of about 20 parts by weight of cyclophosphamide, taken as the anhydride, about 5 to 21 parts by weight of galactitol as excipient, and about 1.4 to 3 parts by weight of water. Preferably, the amount of galactitol is 15-21 parts by weight. The galactitol enhances the chemical and physical stability of the drug and allows faster reconstitution of the formulation in water than mannitol.Type: GrantFiled: June 26, 1986Date of Patent: January 10, 1989Assignee: Cetus CorporationInventor: Daniel L. Francis
-
Patent number: 4794175Abstract: A gene having a DNA sequence complementary to that of the glucoamylase polypeptide mRNA from a fungal species, preferably Aspergillus awamori, is prepared. The mRNA is an approximately 2.2 kilobase poly A RNA obtained from fungal cells grown under conditions of glucoamylase induction. Reverse transcription of the mRNA provides a glucoamylase probe used to identify genomic digest fragments containing glucoamylase gene regions, which are sequenced to locate the introns and exons. The genomic fragments are spliced together to form a gene having a DNA sequence with altered or deleted introns which codes for fungal glucoamylase protein and is capable, when correctly combined with a cleaved DNA expression vector, of expressing a non-native protein having glucoamylase enzyme activity upon transformation of a host organism by the vector. The host is preferably bacteria or yeast. The transformed yeast host may be used to produce ethanol.Type: GrantFiled: April 27, 1987Date of Patent: December 27, 1988Assignee: Cetus CorporationInventors: Jack Nunberg, Jeffrey E. Flatgaard, Michael A. Innis
-
Patent number: 4792523Abstract: The invention concerns positive retroregulatory elements, which when ligated to selected DNA sequences coding for a gene product, enhance the expression of the gene product. Plasmids carrying the positive retroregulatory element ligated to selected DNA sequence and cells transformed by such plasmids are provided AND claimed. In addition, the invention relates to a method for enhancing expression of a gene product by ligating a positive retroregulatory element to a selected DNA sequence expressionable for a desired gene product.Type: GrantFiled: August 31, 1984Date of Patent: December 20, 1988Assignee: Cetus CorporationInventors: Hing C. Wong, Shing Chang
-
Patent number: 4789702Abstract: Polypeptides that are synthesized or expressed directly in microorganisms, include an amino acid sequence that is homologous to at least a portion of gp70 envelope protein of FELV, and are immunogens that elicit or prime a humoral response in cats and immunize cats against FeLV infection. The microbially produced polypeptides are exemplified by a group of E. coli-expressed fusion proteins that comprise a portion of the trp leader peptide and a portion of the trp E protein fused to various portions of a subgroup B gp70 envelope protein. The synthesized polypeptides are exemplified by polypeptides that are homologous to segments of the hydrophilic domains of the gp70 protein.Type: GrantFiled: June 12, 1986Date of Patent: December 6, 1988Assignee: Cetus CorporationInventor: Jack H. Nunberg
-
Patent number: 4789630Abstract: Useful for visualizing biological materials in a solid phase, on a gel, or in a liquid phase is a solid salt of the meriquinone of benzidine or a substituted benzidine. An immobilized or dissolved complex of a polymeric anion and the meriquinone of benzidine or a substituted benzidine having controllable solubility may also be employed. Preferred are meriquinone salts and complexes of 3,3,5,5'-tetramethylbenzidine. For visualization, the benzidine or substituted benzidine is oxidized to its meriquinone at pH 3 to 7 in the presence of an effective anion or polymeric anion, an oxidation catalyst, and an effective amount of oxidant to form a solid salt or immobilized complex of the meriquinone under conditions where the meriquinone solubility lies below about 10.sup.-5 M.Type: GrantFiled: August 20, 1986Date of Patent: December 6, 1988Assignee: Cetus CorporationInventors: Will Bloch, Patrick J. Sheridan, Robert J. Goodson
-
Patent number: 4784949Abstract: A novel universal dominant selectable marker cassette is disclosed. The marker comprises the coding sequences for aminoglycoside phosphotransferase I (APH-I) which has been modified and truncated so as to render its use in recombinant vectors more convenient. The modified, truncated sequence (mtAPH-I) gene is capable, upon expression, of conferring resistance to a number of antibiotics on the host. One of these antibiotics, G418, is toxic to eucaryotic as well as procaryotic hosts. Also disclosed are methods of constructing fusion proteins having N-terminal sequences corresponding to a desired peptide sequence, and C-terminal sequences comprising the amino acids encoded by mtAPH-I.Type: GrantFiled: April 19, 1984Date of Patent: November 15, 1988Assignee: Cetus CorporationInventors: David H. Gelfand, Frances C. Lawyer, Susanne Stoffel
-
Patent number: 4771128Abstract: A method of isolating and purifying toxin conjugates using hydrophobic interaction chromatography. Crude conjugate mixtures are sized to remove unconjugated toxin, and loaded onto a column filled with a suitable hydrophobic gel. Elution is effected with salt solutions of decreasing ionic strength, which salt solutions optionally include increasing amounts of an organic solvent. Toxin conjugate substantially free of unconjugated Ig and unconjugated toxin is provided.Type: GrantFiled: October 10, 1986Date of Patent: September 13, 1988Assignee: Cetus CorporationInventors: Robert Ferris, Walter J. Laird
-
Patent number: 4766106Abstract: A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not readily soluble in water at pH 6-8 without such solubilizing agent, is selectively conjugated to a water-soluble polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols.Type: GrantFiled: January 25, 1988Date of Patent: August 23, 1988Assignee: Cetus CorporationInventors: Nandini Katre, Michael J. Knauf
-
Patent number: 4764465Abstract: A human monoclonal antibody that directly agglutinates type A human red blood cells is described. The exemplified antibody is an IgM and is produced by hybrid cells lines S-H22 and HHA1. The antibody is useful as an ABO typing reagent.Type: GrantFiled: September 30, 1986Date of Patent: August 16, 1988Assignees: Cetus Corporation, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Steven K. H. Foung, Andrew R. Raubitschek, Edgar G. Engleman, F. Carl Grumet, James W. Larrick
-
Patent number: 4762706Abstract: Antibodies exhibit specificity toward single amino acid differences between proteins. These antibodies may be produced by synthesizing a peptide of the appropriate amino acid sequence contained in the protein, immunizing a host with the peptide, and extracting sera from the host to obtain the antibodies. The antibodies and the desired protein are then immunoprecipitated under conditions of partial denaturation to expose the epitope of the protein. The antibodies may be used for diagnostic or therapeutic purposes.Type: GrantFiled: October 17, 1984Date of Patent: August 9, 1988Assignees: Cetus Corporation, Cold Spring Harbor LaboratoriesInventors: Francis P. McCormick, Gail L. Wong, Robin Clark, Norman Arnheim, Danute E. Nitecki, James R. Feramisco
-
Patent number: 4758428Abstract: New multiclass hybrid interferon polypeptides, their corresponding encoding recombinant DNA molecules and transformed hosts which produce the new interferons are described. The amino acid sequences of these hybrids include at least two different subsequences, one of which has substantial homology with a portion of a first class of interferon (e.g., HuIFN-.alpha.) and the other which has substantial homology with a portion of a second class of interferon (e.g., HuIFN-.beta.). Data indicates the interferon activity of .alpha.-.beta. hybrids may be substantially restricted to either cell growth regulatory activity or antiviral activity.Type: GrantFiled: July 15, 1985Date of Patent: July 19, 1988Assignee: Cetus CorporationInventors: David F. Mark, Abla A. Creasey
-
Patent number: 4754065Abstract: Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:[A] [B] Lwhere A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.Type: GrantFiled: July 13, 1987Date of Patent: June 28, 1988Assignee: Cetus CorporationInventors: Corey H. Levenson, Kary B. Mullis
-
Patent number: 4753894Abstract: Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.Type: GrantFiled: January 11, 1985Date of Patent: June 28, 1988Assignee: Cetus CorporationInventors: Arthur E. Frankel, David B. Ring, Michael J. Bjorn
-
Patent number: 4752585Abstract: A biologically active reference therapeutic protein is protected against oxidation by a method involving substituting a conservative amino acid for each methionyl residue susceptible to chloramine T or peroxide oxidation, wherein additional, non-susceptible methionyl residues are not so substituted. The oxidation-resistant mutein so produced is preferably a human mutein of interleukin-2 or interferon-.beta., and the conservative amino acid is most preferably alanine.Type: GrantFiled: August 5, 1986Date of Patent: June 21, 1988Assignee: Cetus CorporationInventors: Kirston E. Koths, Robert F. Halenbeck, Michael A. Innis, Alice M. Wang, Ze'Ev Shaked
-
Patent number: 4751313Abstract: Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:[A][B]Lwhere A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moeity and L is biotin.Type: GrantFiled: July 13, 1987Date of Patent: June 14, 1988Assignee: Cetus CorporationInventors: Corey H. Levenson, Kary B. Mullis
-
Patent number: H494Abstract: Serotype-specific murine anti-Pseudomonas monoclonal antibodies which bind to determinants of the cell wall lipopolysaccharides of P. aeruginosa are prepared from hybrid cell lines. The antibodies may be of any isotype. These antibodies may be used to treat infections caused by P. aeruginosa.Type: GrantFiled: April 26, 1985Date of Patent: July 5, 1988Assignee: Cetus CorporationInventor: James W. Larrick
-
Patent number: D297054Type: GrantFiled: April 16, 1986Date of Patent: August 2, 1988Assignee: Cetus CorporationInventor: Fred G. Williams